Simplified Phenotyping with Dextromethorphan by Thin-Layer Chromatography
- 30 November 1988
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 10 (4) , 490-498
- https://doi.org/10.1097/00007691-198804000-00021
Abstract
Identifying individuals with a deficient capacity for oxidative drug metabolism is of increasing clinical importance. Dextromethorphan (DM) is gaining wide acceptance as a probe drug to characterize individual expression of a specific cytochrome P-450 isozyme. The thin-layer chromatography (TLC) technique described in the present study is a rapid and inexpensive alternative to the methods currently available for assessing the urinary metabolic profile of DM. Sixty-five healthy volunteers participated in the study by ingesting 213 mmol DM and collecting all urine for the ensuing 8 h. Urine samples were analyzed by TLC and high-performance liquid chromatography (HPLC) after treatment with .beta.-glucuronidase. Based on the relative color intensities of DM and its O-demethylated metabolite, dextrorphan, the TLC analysis provided an accurate phenotype assessment. A greater intensity of the parent drug relative to the metabolite indicates a poor metabolizer phenotype whereas a reversed relative intensity indicates the extensive metabolizer phenotype. The phenotype assignments made by TLC were verified by comparison with the quantitative results (based on metabolic ratios) obtained from HPLC analysis. Complete agreement was found between the two methods. The routine implementation of phenotype determination into clinical protocols can be realized with this facile TLC technique.This publication has 21 references indexed in Scilit:
- Quantitative Determination of Dextromethorphan and Three Metabolites in Urine by Reverse-Phase High-Performance Liquid ChromatographyJournal of Pharmaceutical Sciences, 1984
- Inter-individual variation in the metabolism of dextromethorphanInternational Journal of Pharmaceutics, 1983
- SUBSTRATE-SPECIFICITY OF THE FORM OF CYTOCHROME-P-450 CATALYZING THE 4-HYDROXYLATION OF DEBRISOQUINE IN MAN1983
- Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.BMJ, 1982
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Sparteine metabolism in Canadian CaucasiansClinical Pharmacology & Therapeutics, 1981
- The urinary excretion of dextromethorphan and three metabolites in dogs and humansToxicology and Applied Pharmacology, 1980
- Hypotensive response to debrisoquine and hydroxylation phenotypeLife Sciences, 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Determination of Dextrorphan in Plasma and Evaluation of Bioavailability of Dextromethorphan Hydrobromide in HumansJournal of Pharmaceutical Sciences, 1977